|
|
|
|
pmid:2353317
|
|
|
|
|
pmid:8901008
|
Kondo T et al. |
Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism. |
|
Epilepsia |
pmid:1733753
|
Kassahun K and Baillie TA |
Cytochrome P-450-mediated dehydrogenation of 2-n-propyl-2(E)-pentenoic acid, a pharmacologically-active metabolite of valproic acid, in rat liver microsomal preparations. |
|
Drug Metab. Dispos. |
pmid:8097692
|
|
|
|
|
pmid:
|
Nau H and Zierer R |
Pharmacokinetics of valproic acid and metabolites in mouse plasma and brain following constant-rate application of the drug and its unsaturated metabolite with an osmotic delivery system. |
|
Biopharm Drug Dispos |
pmid:6819013
|
Altrup U et al. |
Effects of valproate in a model nervous system (buccal ganglia of Helix pomatia): II. Epileptogenic actions. |
|
Epilepsia |
pmid:1628594
|
Altrup U et al. |
Effects of valproate in a model nervous system (buccal ganglia of Helix pomatia): I. Antiepileptic actions. |
|
Epilepsia |
pmid:1628593
|
Anderson GD et al. |
Effect of valproate dose on formation of hepatotoxic metabolites. |
|
Epilepsia |
pmid:1628592
|
Kondo T et al. |
Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia? |
|
Epilepsia |
pmid:1350534
|